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Abstract
Background: Experimental studies support an important role for endothelial nitric oxide synthase
(eNOS) in the regulation of angiogenesis. In humans, a common polymorphism exists in the eNOS
gene that results in the conversion of glutamate to aspartate for codon 298. In vitro and in vivo
studies have suggested a decreased NOS activity in patients with the Asp298 variant. We
hypothesized that a genetic-mediated decreased eNOS activity may limit collateral development in
patients with chronic coronary occlusions.
Methods: We selected 291 consecutive patients who underwent coronary angiography and who
had at least one chronic (>15 days) total coronary occlusion. Collateral development was graded
angiographically using two different methods: the collateral flow grade and the recipient filling
grade. Genomic DNA was extracted from white blood cells and genotyping was performed using
previously published techniques.
Results: Collateral development was lower in patients carrying the Asp298 variant than in Glu-Glu
homozygotes (collateral flow grade: 2.64 ± 0.08 and 2.89 ± 0.08, respectively, p = 0.04; recipient
filling grade: 3.00 ± 0.08 and 3.24 ± 0.07, respectively, p = 0.04). By multivariable analysis, three
variables were independently associated with the collateral flow grade: female gender, smoking, and
the Asp298 variant (p = 0.03) while the Asp298 variant was the sole variable independently associated
with the recipient filling grade (p = 0.03).
Conclusion: Collateral development is lower in patients with the Asp298 variant. This may be
explained by the decreased NOS activity in patients with the Asp298 variant. Further studies will
have to determine whether increasing eNOS activity in humans is associated with coronary
collateral development.
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In spite of recent advances in the techniques used for myo-
cardial revascularization, chronic total coronary occlu-
sions are frequently observed in patients with coronary
artery disease. This could lead to symptoms of angina,
quality of life impairment, left ventricular dysfunction,
and prognosis worsening. In the case of severe stenosis or
total occlusion of a coronary artery, the collateral circula-
tion may be an alternative source of blood supply to the
myocardium at risk [1,2]. Although some factors, such as
the duration of myocardial ischemic symptoms, have
been associated with the extent of collateralization, coro-
nary collateral development remains difficult to anticipate
and there is considerable inter-individual variability in
this process [3]. One emerging concept in cardiovascular
diseases, which could explain this variability, is the possi-
ble interaction between genetic determinants and the
pathophysiological responses to cardiac injury.
Among candidate genes that may be implicated in collat-
eral development is the endothelial nitric oxide synthase
(eNOS) gene. Experimental studies support an important
role for eNOS in the regulation of angiogenesis [4]: mice
lacking eNOS gene have severely reduced angiogenesis in
response to tissue ischemia [5,6] while eNOS overexpres-
sion enhances angiogenesis [7-9]. In humans, different
common polymorphisms exist in the eNOS gene and
among them one that results in the conversion of gluta-
mate to aspartate for codon 298. In vitro studies have sug-
gested that the Asp298 variant may be functional and
associated with a decreased of eNOS activity [10]. In vivo
studies have documented an increased reactivity to alpha-
adrenergic stimulation in patients with the Asp298 variant
suggesting a decreased NOS activity [11].
In the present study, we hypothesized that a genetic-medi-
ated decreased eNOS activity may limit collateral develop-
ment in patients with chronic coronary occlusions. We
studied 291 patients with chronic coronary occlusions in
whom collateral development was graded angiographi-
cally. We show that patients with the Asp298 variant have




Between May 2000 and October 2001, 2050 consecutive
patients who underwent a coronary angiography at our
institution were enrolled in a registry. All patients gave
informed consent and had blood and serum samples that
were stored at -80°C until further analysis. The baseline
clinical and angiographic characteristics were prospec-
tively recorded by trained physicians.
For the purpose of this study, we selected all patients who
had at least one chronic (>15 days) total occlusion of a
major coronary vessel. The patients with a history of cor-
onary artery bypass graft were excluded. Two hundred and
ninety one patients were thus selected to form the study
population.
Angiography procedure and coronary collaterals grading
Selective coronary angiography was performed in multi-
ple orthogonal projections using the Judkins technique.
In case of significant lesion (stenosis or total occlusion),
there was an intracoronary nitrates infusion. Collateral
development was graded using two different methods by
two independent observers. These methods have been
previously validated [12].
The collateral flow grade evaluates the flow in the collateral:
0 = no flow in the collateral; 1 = the collateral is barely
apparent; dye is not visible throughout the cardiac cycle
but is present in at least 3 consecutive frames; 2 = the col-
lateral is moderately opaque but is present throughout at
75% of the cardiac cycle; 3 = the collateral is well opacified
and the column of dye is well defined but is < 0.7 mm
wide throughout the majority of its length; 4 = the collat-
eral is well opacified, fills antegrade, and is very large.
The second method was the recipient filling grade: 0 = no
angiographically apparent collaterals; 1 = apparent collat-
erals extend into a region of myocardium with no angio-
graphically apparent recipient vessel; 2 = minimal
recipient filling by collaterals is manifested by minor side
branch filling and no epicardial artery or epicardial side
branch filling; 3 = Moderate recipient filling by collaterals
is manifested by complete filling of epicardial side
branches and partial filling of a major epicardial artery; 4
= there is complete filling of a major epicardial segment.
Genetic analysis
Blood samples were collected at the time of coronary ang-
iography. Genomic DNA was extracted from white blood
cells by a « salting out » procedure as previously described
[13]. DNA fragment – including the G/T translation in the
exon 7 – amplification was performed by Polymerase
Chain Reaction (PCR). Primers and PCR conditions used
for eNOS have been reported previously [14]. The prod-
ucts was digested by the Ban II enzyme for genotyping as
previously described [14] and the results of the genotyp-
ing were tested for the Hardy-Weinberg equilibrium (p >
0.05).
Statistical analysis
Patients were grouped on the basis of the presence or
absence of the Asp298 variant (Asp298 homozygotes and
heterozygotes were combined and compared to the
homozygotes Glu298) as previously reported [11,14-16].Page 2 of 6
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before analyses. Since the distribution were normal, they
were presented as mean ± SEM and were compared with
use of the bilateral unpaired Student' t test. Qualitative
variables were compared with use of the Pearson chi-
square test or the Fisher exact test when necessary. Multi-
variable analysis was performed with use of a general lin-
ear model (GLM) adjusted for age, gender, smoking,
hypertension, hypercholesterolemia and diabetes melli-
tus. Statistical analysis were performed with the SAS soft-
ware, version 8 (SAS Institute Inc., Cary, NC, USA).
Results
The baseline characteristics of the study population are
shown in table 1. There were no statistically significant
differences between patients with the Asp298 variant and
Glu-Glu homozygotes. Most patients were male with a
mean age of 63 ± 11 years and with a high prevalence of
cardiovascular risk factors. Notably, 77% of the patients
were current or past smokers and 36% were diabetics. Car-
diovascular medications did not differ between the two
groups. The angiographic severity of coronary atheroscle-
rosis was similar in the two groups. In most of the cases,
only one coronary artery was totally occluded.
Table 1: Demographics and medical therapy at baseline by genotype
Asp298 (n = 168) Glu-Glu (n = 123) All patients (n = 291) p
Age, years 63 ± 11 62 ± 11 63 ± 11 0.92
Female gender, % 18 20 19 0.72
Body mass index, kg/m2 28.3 ± 4.7 27.8 ± 4.6 28.1 ± 4.6 0.32
Risk factors, %
Smoking 76 78 77 0.71
Hypercholesterolemia 76 81 78 0.29
Hypertension 54 55 55 0.86
Diabetes mellitus 35 37 36 0.80
Familial history of CAD 37 35 36 0.18
Clinical symptoms, %
Stable 73 78 75 0.35
Unstable 27 22 25
Angiographic data:
No. of vessels with > 50% stenosis, %
1 vessel 24 25 25
2 vessels 38 34 36 0.92
3 vessels 38 41 39
No. of vessels with total occlusion, %
1 vessel 85 83 84 0.61
2 vessels 15 17 16
Occluded LAD, % 38 29 34 0.12
Occluded Cx, % 17 22 19 0.32
Occluded RCA, % 60 66 62 0.27
Cardiovascular medications, %
ASA 78 78 78 0.96
ACE inhibitors 55 52 54 0.57
ARB 6 10 8 0.24
Beta-blockers 63 58 61 0.34
Nitrates 58 48 54 0.09
Calcium antagonists 24 31 27 0.20
Statins 63 58 61 0.34
Data are presented as percent of patients or mean value ± SD
CAD = coronary artery disease; MI, myocardial infarction
LAD = left anterior descending artery; Cx = circumflex; RCA = right coronary artery
ASA = acetylsalicylic acid; ACE = angiotensin-converting enzyme; ARB = angiotensin 2 receptor blockers.Page 3 of 6
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grade was 2.75 ± 0.06 and the mean recipient filling grade
was 3.10 ± 0.06. By univariable analysis, angiographic evi-
dence of collateral development was lower in patients car-
rying the Asp298 variant than in Glu-Glu homozygotes
(collateral flow grade: 2.64 ± 0.08 and 2.89 ± 0.08, respec-
tively, p = 0.04; recipient filling grade: 3.00 ± 0.08 and
3.24 ± 0.07, respectively, p = 0.04). When patients were
classified into 3 groups (Glu-Glu homozygotes, Glu-Asp
heterozygotes, Asp-Asp homozygotes), respective values
for collateral flow grade were 2.84 ± 0.08, 2.63 ± 0.09, and
2.69 ± 0.23, while respective values for recipient filling
grade were 3.24 ± 0.07, 3.01 ± 0.08, and 2.94 ± 0.23. Inde-
pendent predictors of collateral development were then
determined by multivariable analysis (table 2). When
considering the collateral flow grade, three variables were
independently associated with an impaired collateral
development: female gender, smoking, and the Asp298 var-
iant; there was also a strong trend for a deleterious effect
of diabetes mellitus on collateral development. When
considering the recipient filling grade, the Asp298 variant
was the sole variable independently associated with an
impaired collateral development; again, the presence of
diabetes mellitus was associated with a trend for a delete-
rious effect. The presence of the Asp298 variant was there-
fore the sole independent predictor of both the collateral
flow grade and the recipient filling grade.
Since collateral vessel development has been associated
with a preserved left ventricular function in the case of
total occlusion of a coronary artery [17], we compared the
left ventricular ejection fraction in both groups. A recent
evaluation of left ventricular ejection fraction was availa-
ble in 162 (96%) of patients with the Asp298 variant and
in 120 (98%) of Glu-Glu homozygotes. The mean ( ± SD)
left ventricular ejection fraction was 53 ± 16% in the over-
all study population and was 50 ± 16% in patients with
the Asp298 variant versus 54 ± 16% in Glu-Glu homozy-
gotes (p = 0.05).
Discussion
In the present study, we found that patients carrying the
Asp298 variant of eNOS gene had significantly less angio-
graphic evidence of collateral vessel formation in response
to total coronary occlusion. Multivariable analysis
showed that this effect was independent of other factors
that influence collateral vessel formation.
Nitric oxide (NO), constitutively produced by endothelial
nitric oxide synthase (eNOS), plays critical roles in vascu-
lar biology, including regulation of vascular tone and
blood pressure. In addition to its vasodilatory properties,
NO has been implicated in the modulation of angiogen-
esis [4]. Ziche et al. suggested that NO may play a role in
angiogenesis elicited by VEGF but not by FGF [18]. Muro-
hara et al. demonstrated that angiogenesis developing in
response to limb ischemia was severely reduced in mice
lacking eNOS gene [5]. Moreover, eNOS over expression
in transgenic mice [8] or using gene transfer strategies
[7,9] enhances angiogenesis in response to tissue
ischemia. There is thus strong experimental evidence to
support an important role for eNOS in the regulation of
angiogenesis in animal models, however the implication
of eNOS activity in collateral vessel formation in response
to myocardial ischemia in humans remains unknown
ENOS is encoded by a 26-exon gene located on chromo-
some 7 [19]. In view of the physiological and pathophys-
iological importance of NO, the potential role of eNOS in
the pathogenesis of various human diseases has been
examined using its polymorphic variants as potential dis-
ease markers. Different common polymorphisms exist
and among them one in nucleotide 894 (G-T) that results
in the conversion of glutamate to aspartate for codon 298.
A study by Philip et al. has documented in vivo an
increased reactivity to alpha-adrenergic stimulation in
patients with the Asp298 variant suggesting a decreased
NOS activity [11]. In recent clinical studies, the Asp298 var-
iant has been implicated as a risk factor for coronary artery
disease [20], hypertension [16], or has been associated
with a poorer event-free survival in patients with conges-
tive heart failure [14]. In a meta-analysis of 26 studies
involving 23028 subjects, homozygosity for Asp298 was
associated with increased risk of ischemic heart disease by
31% [15]. When taken together with the results of the
present study, the above described literature suggests that
a decreased NOS activity in coronary vessels of patients
with the Asp298 variant may explain the decreased collat-
eral vessel formation observed in this subgroup of
patients. The mechanism by which the Asp298 variant
could decrease the eNOS activity remains unclear. The
Asp298 variant has been associated with an increased sus-
ceptibility to enzymatic cleavage [10] but it has been sug-
gested that the increased susceptibility to proteolytic
cleavage of NOS could result from sample preparation
Table 2: Predictors of collateral development: multivariable 
analysis
Collateral flow grade Recipient filling grade
β p β p
Age ≥ 63 - 0.04 0.72 + 0.03 0.77
Female gender - 0.49 0.009 - 0.22 0.23
Smoking - 0.34 0.05 - 0.12 0.47
Hypertension - 0.04 0.72 - 0.04 0.74
Hypercholesterolemia - 0.01 1.00 - 0.16 0.23
Diabetes mellitus - 0.23 0.06 - 0.20 0.09
Asp298 variant - 0.26 0.03 - 0.24 0.03Page 4 of 6
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association between the Asp298 variant and eNOS activity
[22,23]. An other possible explanation is that the variant
Asp298 may simply be a genetic marker. For example, the
Asp298 variant is in linkage disequilibrium with an other
polymorphism resulting in a nucleotide substitution in
the promoter region (T/C -786) of the eNOS gene [24,25].
It has been shown that the rarer variant (C) suppresses
eNOS transcription by approximately 50%. The Asp298
could be a marker of the occurrence of the unfavorable
"C" allele in the promoter region, the latter responsible
for the decreased of eNOS activity.
In the present study, collateral vessel formation was
assessed using angiographic criteria. Angiographically vis-
ible collaterals represent only a fraction of the total collat-
eral vessels because collaterals are angiographically
demonstrable only when they reach 200 µm [12]. Several
studies have shown that assessing the collateral circula-
tion by intracoronary Doppler flow or pressure wires may
be an interesting alternative to determine collateral blood
flow in humans [26,27]; however, the invasive nature of
this method which imply to cross the occlusion site by a
guide wire would limit its interest in a genetic association
study like the present one in which inclusion of consecu-
tive and as much as possible unselected cases is manda-
tory to provide unbiased results. In an attempt to provide
a rigorous, systematic analysis of human coronary angio-
genesis by angiography, we used two criteria recently
reviewed by Gibson et al. [12]. The collateral flow grade
focuses on the development of the collateral network
itself while the recipient filling grade is adapted from the
Rentrop grade [28] and provides information on how the
recipient vessel is filled by the collaterals. In the present
study, the fact that the deleterious impact of the Asp298
variant was evident with both criteria reinforces our find-
ings. An important question in the present study is to
know whether the better angiographic criteria in Glu-Glu
homozygotes are a result of the vasodilation properties of
eNOS or are due to an increase in blood vessel growth.
Such a question is beyond the scope of this clinical study
but a direct effect of eNOS on angiogenesis has been doc-
umented in the above described experimental studies [7-
9]. Moreover, the trend for higher left ventricular ejection
fraction observed in Glu-Glu homozygotes suggests a ben-
eficial effect of the collaterals on myocardial function.
Finally, our analysis was based on a single time point; fur-
ther assessment of collateral development by repeated
angiographic follow-up would be of interest but was not
performed due to the invasive nature of coronary
angiography.
Conclusion
In conclusion, this investigation is the first study to show
the relationship between the 894 (G-T) eNOS polymor-
phism and coronary collaterals in humans. It demon-
strates that collateral development is poorer in patients
with the Asp298 variant. This may be explained by a
decreased NOS activity in patients with the Asp298 variant.
Further studies will have to determine whether increasing
eNOS activity in humans is associated with coronary col-
lateral development.
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